ISRCTN46335400已完成2 期
A phase II/III, observer-blind, randomised, active controlled study to compare the safety and immunogenicity of a meningococcal A conjugate vaccine (PsA-TT) with meningococcal ACWY polysaccharide vaccine administered in healthy children 2 to 10 years of age
Serum Institute of India Limited (SIIL)0 个研究点目标入组 340 人开始时间: 2007年8月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 340
研究概览
简要总结
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553690 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553684 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553670
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 2 to 10 years of age (both included)
- •2. Written informed consent obtained from parents or legal guardian of the child
- •3. Free of obvious health problems as established by medical history including physical examination and clinical judgment of the investigator
- •4. Parents or legal guardian capable and willing to bring their child or to receive home visits (for their child) for all follow-up visits
- •5. Residence in the study area
- •6. Fully vaccinated according to the local Expanded Program on Immunisation (EPI) schedule
排除标准
- •1. Previous vaccination against Neisseria meningitidis
- •2. Known exposure to Neisseria meningitidis during the three previous months
- •3. History of allergic disease or known hypersensitivity to any component of the two study vaccines and/or following administration of vaccines included in the local program of immunisation
- •4. Administration of any other vaccine within 60 days prior to administration of study vaccines or planned vaccination during the first 28 days after the study vaccination
- •5. Use of any investigational or non-registered drug within 90 days prior to the administration of study vaccines
- •6. Administration of immunoglobulins and/or any blood products within 30 days prior to the administration of study vaccines or planned administration during the study period
- •7. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents within 90 days prior to the administration of study vaccines (including systemic or inhaled corticosteroids, this means prednisone, or equivalent, greater than 0.5 mg/kg/day; topical steroids are allowed)
- •8. A family history of congenital or hereditary immunodeficiency
- •9. History of meningitis or seizures or any neurological disorder
- •10. Major congenital defects or serious chronic illness, including malnutrition (as per investigator's judgment)
- •11. Acute disease at the time of enrolment (acute disease is defined as the presence of a moderate or severe illness with or without fever) is a temporary exclusion
- •12. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination or laboratory tests, which in the opinion of the investigator, might interfere with the study objectives
- •13. Any condition or criteria that in the opinion of the investigator might compromise the well being of the subject or the compliance with study procedures or interfere with the outcome of the study
- •14. Non residence in the study area or intent to move out within one year
研究者
相似试验
已完成
2 期
A phase II/III, observer-blind, randomised, active controlled study to compare the safety and immunogenicity of a meningococcal A conjugate vaccine (PsA-TT) with meningococcal ACWY polysaccharide vaccine administered in healthy subjects 2 to 29 years of ageBacterial meningitisInfections and InfestationsMeningitisISRCTN87739946Serum Institute of India Limited (SIIL)900
已完成
2 期
A phase II, double-blind, randomised, controlled, dose ranging study to evaluate the safety, immunogenicity, dose response and schedule response of a meningococcal A conjugate vaccine administered concomitantly with local expanded program on immunisation (EPI) vaccines in healthy infantsBacterial meningitisNervous System DiseasesISRCTN82484612Serum Institute of India Limited1,200
已完成
2 期
A phase II, observer-blind, randomised, active controlled study to compare the safety, immunogenicity, and induction of immunological memory of a meningococcal A conjugate vaccine, a meningococcal ACYW polysaccharide vaccine and a hib conjugate vaccine, administered in healthy toddlers 12 - 23 months of ageISRCTN78147026Serum Institute of India Limited (SIIL)600
已完成
不适用
PREoperative intraVENous iron To Treat anaemia in major surgery (PREVENTT)ISRCTN67322816niversity College London (UK)487
已完成
1 期
A phase I, double-blind, randomized study to evaluate the safety and immunogenicity of a new Meningococcal A Conjugate vaccine versus a Meningococcal Polysaccharide A+C reference vaccine and a Tetanus Toxoid control vaccine, given as single intramuscular injections in healthy adults from 18 to 35 years of age (India)Meningococcal diseaseInfections and InfestationsISRCTN17662153Serum Institute of India Limited (SIIL) (Secondary Sponsor - Program for Appropriate Technology in Health [PATH], USA)72